Tafinlar-Mekinist Combination Shows Significant Benefit in BRAF V600E/K Population

FDA grants RP1 BLA priority review for advanced melanoma

FDA has accepted the Biologics License Application from Replimune Group Inc. for RP1 (vusolimogene oderparepvec) in combination with nivolumab (Opdivo) for patients with advanced melanoma.

January 24, 2025

Vol.51 No.03

In Brief

Becky Kamowitz named executive director of the Skin Cancer Foundation

Becky Kamowitz was named executive director of the Skin Cancer Foundation, a national nonprofit organization that is committed to decreasing the incidence and mortality skin cancer through public education. Kamowitz has worked for the foundation for more than a decade and previously served as interim executive director and senior director of marketing communications.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma

FDA approved Unloxcyt (osibelimab-ipdl), a programmed death ligand-1 blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Remote telemedicine tool found highly accurate in diagnosing melanoma

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.

November 22, 2024

Vol.50 No.44

Clinical Roundup

UVA Health tests focused ultrasound to increase immune response in melanoma

A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

FDA approved an Investigational Device Exemption application to initiate a multi-center study for the treatment of recurrent cutaneous squamous cell carcinoma in immunocompromised patients using the Alpha DaRT.

October 11, 2024

Vol.50 No.38

Tafinlar-Mekinist Combination Shows Significant Benefit in BRAF V600E/K Population

YOU MAY BE INTERESTED IN

FDA grants RP1 BLA priority review for advanced melanoma

Becky Kamowitz named executive director of the Skin Cancer Foundation

FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma

Remote telemedicine tool found highly accurate in diagnosing melanoma

UVA Health tests focused ultrasound to increase immune response in melanoma

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

Renew today!

Subscriber content

Never miss an issue!

Login